Targeting IL2, IL12, and IL13 in the brain may be key to treating “COVID brain.” — COVID-19 patients can develop a number of neurological symptoms during the acute phase of the disease. These include loss of smell, cognitive problems, headaches, dizziness, and even delirium, which is characterized by severe cognitive disturbances such as altered consciousness, altered attention, and confusion. In fact, 20–30 percent of COVID-19 patients…